PUNE, India, December 3, 2015 /PRNewswire/ --
ReportsnReports.com adds "Mantle Cell Lymphoma - Pipeline Review, H2 2015" market research report analyzing 43 companies, supported with 67 tables and 16 figures and providing an overview of the therapeutics pipeline for Mantle Cell Lymphoma.
This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects. Complete report on Mantle Cell Lymphoma Pipeline Review analyzing 43 companies and supported with 67 tables and 16 figures is now available at http://www.reportsnreports.com/reports/444214-mantle-cell-lymphoma-pipeline-review-h2-2015.html .
The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Top companies mentioned in this report are AB Science SA, AbbVie Inc., Acetylon Pharmaceuticals, Inc., Actinium Pharmaceuticals, Inc., Advancell, Affimed Therapeutics AG, Amgen Inc., Astellas Pharma Inc., Astex Pharmaceuticals, Inc., Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Cellular Biomedicine Group, Inc., Eisai Co., Ltd., Eli Lilly and Company, EpiZyme, Inc., Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline Plc, Hutchison MediPharma Limited, ImmunoGen, Inc., Immunomedics, Inc., Incyte Corporation, Infinity Pharmaceuticals, Inc., Johnson & Johnson, Karyopharm Therapeutics, Inc., LFB S.A., MedImmune, LLC, Merck & Co., Inc., Millennium Pharmaceuticals, Inc., MorphoSys AG, Nordic Nanovector ASA, Novartis AG, Onconova Therapeutics, Inc., Onyx Pharmaceuticals, Inc., Pfizer Inc., Pharmacyclics, Inc., Portola Pharmaceuticals, Inc., Seattle Genetics, Inc., Selvita SA, Sorrento Therapeutics, Inc., Stemline Therapeutics, Inc. and TG Therapeutics, Inc. Order a copy of Mantle Cell Lymphoma Pipeline Review market research report at http://www.reportsnreports.com/purchase.aspx?name=444214 .
Drug profiles discussed in this report are 13197, AB-8779, abemaciclib, abexinostat hydrochloride, acadesine, acalisib, ACP-196, ACY-775, AFM-11, agatolimod sodium, alisertib, AMG-319, ASN-002, AT-7519, bendamustine hydrochloride, Betalutin, BLyS-gel, BMS-986016, buparlisib hydrochloride, Carfilzomib, CBM-C19.1, CBM-C20.1, CC-122, Cell Therapy for Oncology, Cell Therapy to Target CD19 for Oncology, Cell Therapy to Target ROR1 for Oncology, cerdulatinib, copanlisib hydrochloride, daratumumab, denintuzumab mafodotin, duvelisib, E-7449, entospletinib, epratuzumab, EPZ-015666, HMPL-523, ibrutinib, ibrutinib + ublituximab + TGR-1202, idelalisib, IGN-002, IMGN-529, IMMU-114, INA-01, INCB-39110, INCB-40093, inebilizumab, ixazomib citrate, JNJ-64052781, lenalidomide, MEDI-0680, MEDI-551 + MEDI-0680, Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies, Monoclonal Antibody Conjugate to Target CD45 for Oncology, MOR-208, ON-123300, ONC-201, pevonedistat hydrochloride, polatuzumab vedotin, ribociclib, SEL-120, selinexor, SGN-CD70A, SL-101, Small Molecule for Mantle Cell Lymphoma, temsirolimus, TGR-1202, tisagenlecleucel-T, tretinoin, ublituximab, venetoclax and vorinostat.
Another newly published market research titled Brain Cancer - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Complete report on Brain Cancer Pipeline Review market research report of 311 pages is available at http://www.reportsnreports.com/reports/444200-brain-cancer-pipeline-review-h2-2015.html .
Explore more reports on Pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
+ 1 888 391 5441
Connect With Us on:
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts